AGOMELATINE (cas 138112-76-2)-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus

Add time:08/20/2019    Source:sciencedirect.com

Brain-derived neurotrophic factor (BDNF) is a neurotrophin that serves as a survival factor for neurons. Agomelatine is a novel antidepressant as well as a potent agonist of melatonin (MT), MT1 and MT2 receptor types and an antagonist of the serotonin (5HT), 5-HT2C receptor. The study herein established whether treatment with agomelatine alters hippocampal BDNF protein expression under chronic unpredictable mild stress (CUMS) condition. Twenty-one day treatment with agomelatine, fluoxetine or vehicle was assessed in 52 Sprague-Dawley rats undergoing CUMS. Ten naïve control rats were also evaluated after 21 days. The behavioral effects of treatments were studied using the open field test (OFT) on day 0, 7 and 21 and sucrose preference test on day 21. Hippocampal BDNF protein expression was measured using immunohistochemistry. The effect of the interventions on hippocampal neurons was histologically examined after H&E staining. Agomelatine mitigated the reduction in rearing behavior by CUMS in the OFT on day 7 as well as sucrose preference on day 21. The mean optical density value of BDNF was significantly higher in the CUMS + agomelatine group than the CUMS and CUMS + fluoxetine groups. The CUMS + agomelatine group had a significantly higher number of BDNF positive cells compared to naïve controls and CUMS group. Histology showed that hippocampal neurons in the CUMS + agomelatine and CUMS + fluoxetine groups were intact and few of them demonstrated karyopyknosis. Agomelatine–a novel antidepressant, but not fluoxetine, increased hippocampal BDNF level and of BDNF positive neurons in rats subject to CUMS.

We also recommend Trading Suppliers and Manufacturers of AGOMELATINE (cas 138112-76-2). Pls Click Website Link as below: cas 138112-76-2 suppliers

Prev:Oxymatrine ameliorates AGOMELATINE (cas 138112-76-2)-induced hepatocyte injury through promoting proteasome-mediated CHOP degradation
Next:Spike–Wave Discharges and Sleep–Wake States during Circadian Desynchronization: No Effects of AGOMELATINE (cas 138112-76-2) upon Re-Entrainment)